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Abstract
Background: To advance the treatment of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP),
randomised controlled therapeutic studies with appropriate and sensitive outcomes are reuired. One candidate
outcome is the 10-metre walk test (10MWT), a patient-centred, simple and functional measure. To calculate sample size
based on 10MWT as the primary outcome, variability within and between subjects must be known.
Methods: Data on 10MWT from 76 patients with HAM/TSP were prospectively collected from four specialist centres in
Brazil, Japan, USA and UK. Data, collected at two time points, 6 months apart, were log transformed and subjected to
analysis of covariance.
Results: Baseline mean (standard deviation = SD), median 10MWT were 23.5 (18.9), 16.3 s/10 m and at 6 months 24.9
(23.9), 16.4 s/10 m. The mean (SD) % increase in walk time was 5.74 % (28.2 %). After logarithmic transformation, the
linear correlation between baseline and 24 weeks 10MWT was r = 0.938. Using these data, it was determined that a
randomised controlled trial with 30 participants per group would have 90 % power to detect a 19 % decrease or a
23 % increase in 10MWT.
Conclusions: The intra-patient variability of 10MWT is relatively small in HAM/TSP over 6 months. 10MWT is a feasible
outcome measure for a clinical trial in HAM/TSP. To our knowledge, this is the first ever recommendation for the sample
size required for trials in HAM/TSP patients.
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Background
HTLV-1-associated myelopathy/tropical spastic paraparesis
(HAM/TSP) is a neuroinflammatory disease of the spinal
cord caused by the retrovirus human T lymphotropic virus
type 1 (HTLV-1) [1]. HTLV-1 is also known to be the cause
of an aggressive haematological malignancy, adult T cell
leukaemia/lymphoma (ATLL) [2]. Having some features
similar to multiple sclerosis, and often being of insidious
onset, HAM/TSP is difficult to diagnose. Symptoms are
usually confined to the lower body. Patients typically com-
plain of stiffness and weakness of the legs, falls, pain in the
lower back and legs, urinary urgency, constipation and
erectile dysfunction. The majority of patients develop a
chronically progressing disability, and 50 % become
wheelchair-dependent within 2 decades of onset. A small
subset progresses rapidly and a third group minimally [3].
Specific diagnostic criteria have been developed to differen-
tiate HAM/TSP from other myelopathies [4].
Thirty years after the discovery of HTLV, there is still no
internationally recognised treatment available for HTLV-1
infection or HAM/TSP. Clinical scientists are keen to find
effective therapy for HAM/TSP. This is ideally proven
through a double-blind, randomised, controlled trial (DB
RCT) with a well-defined, primary outcome measure,
tested in a sufficiently large, well-described, patient cohort.
Designing such a trial for HAM/TSP patients has been
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proven challenging, as addressed by Martin et al. previ-
ously [5].
In the process of designing a HAM/TSP clinical trial that
meets all the desirable criteria, an international HAM/TSP
clinical trial study group (HAM/TSP CTSG) consisting of
HAM/TSP experts from Brazil, Japan, UK and USA was
formed. The aim of this group was to collaboratively de-
sign a DB RCT approved by all consortium members and
to gain access to a large enough HAM/TSP patient cohort.
This would allow adjustment of outcome of HAM/TSP
patients by variables such as subgroup, gender and baseline
disability as well as a short trial recruitment phase, to min-
imise trial costs.
There is no uniformly recognised reliable biomarker of
treatment response in HAM/TSP. The HAM/TSP CTSG
therefore chose to evaluate the potential of a clinical out-
come measure, the 10-metre walk test (10MWT) as a pri-
mary outcome measure. 10MWT measures the time a
patient takes to walk 10 m in a straight line using their
usual walking aid and is presented as seconds/10 m. A
decrease in 10MWT thus represents improved mobility.
10MWT was chosen for three reasons: (i) When surveyed
HAM/TSP patients felt that improving their gait should be
a primary goal of a new intervention, making this a patient-
centred measure, (ii) 10MWT has been used routinely to
monitor patient mobility in all four HTLV treatment cen-
tres and (iii) 10MWT is a validated disability outcome
measure used in other trials of patients with impaired mo-
bility [6], such as patients with stroke [7], spinal cord injury
[8], Parkinson’s disease [9] and multiple sclerosis [10].
Healthy individuals are reported to complete the
10MWT in a mean of 6.84 s [11]. In a study of HAM/TSP
patients, the overall mean 10MWT in 29/49 (81 %) patients
increased by +4.25 s/10 m in 12 months (range −0.13 to
24.6, median 1.27). 10MWT deteriorated even in patients
who walked without any need for further aid by a median
of +1.98 s/10 m/year3. It is worth noting that the measure-
ment of 10MWT varies considerably within and between
patients on a daily basis, over time, and is operator-
dependent.
The standard method to calculate the sample size of a
clinical trial is the power calculation [12]. In order to be
able to calculate the sample size required to have a high
probability to refute the null hypothesis, should the treat-
ment really be effective compared to the comparator, the
inter- and intra-patient variabilities of 10MWT over time
needed to be taken into account. To this aim, the HAM/
TSP CTSG submitted prospectively collected 10MWT
data of HAM/TSP patients to two biostatisticians.
Methods
10MWT data collected as part of HAM/TSP patients’
clinical routine workup at four HTLV treatment centres
were submitted for use in the sample size calculation.
Anonymised data were submitted from the HTLV Centre
at Bahiana Medical School, Salvador, Brazil; Department of
Rare Diseases Research, Institute of Medical Science, St.
Marianna University School of Medicine, Japan; National
Centre for Human Retrovirology, St. Mary’s Hospital,
Imperial College Healthcare NHS Trust, UK; and
Neuroimmunology Branch, NIH, USA. In communication
with local research and/or ethics review committees of all
four countries, it was agreed that patient consent and com-
mittee permissions were not required. The UK’s Health
Research Authority guidelines advise that the secondary
use of data collected for clinical purposes can be used in
research without requiring ethical review, provided the
data are anonymised to the research team [13].
Included were 10MWT data on patients with definite
HAM/TSP as defined by Belem Criteria [4], >18 years old,
who could walk 10 m, had at least two 10MWT measure-
ments 6 months apart. Data on gender, age, duration of
HAM/TSP and walking aid were collected.
10MWT was measured by trained clinical staff following
internationally used standard operating procedures, by
measuring the time a patient needed to walk a straight
10-m long line in seconds [3, 14].
Statistical considerations
For use as an outcome variable in a trial, we need to de-
scribe and to check the distribution of 10MWT. If the dis-
tribution is non-normal, a transformation such as the
logarithm or square root function can be applied to get a
normal distribution. Data would be suitable for statistical
analysis if the scatter plot of 10MWT at 6 months against
10MWT at baseline gives a uniform cloud of points. The
correlation between baseline and 6-month measurement
was calculated (r). For sample size calculations, the stand-
ard deviation (SD) at 6 months was multiplied by √(1− r2)
to allow for the effect of analysis of covariance on the base-
line measure [15].
Results and discussion
Longitudinally collected 10MWT of patients with definite
HAM/TSP, spanning 6 months, were included. Matched
10MWT at baseline and at 6 months were available for a
total of 76 patients: three subjects from Brazil, 41 from
Japan, 27 from UK and five from the USA.
Demographic data were available for 70 (92 %) pa-
tients: 59 (84 %) were female, mean age was 54 years
(range 20–83), mean duration of HAM/TSP was 11 years
(1–37), 22 (31 %) patients did not need a walking aid, 25
(36 %) needed one walking stick, 16 (23 %) needed two
and 2 (3 %) a tripod.
At baseline, the mean and SD of 10MWT was 23.5 (18.9)
s/10 m and the median 16.3 s/10 m. At 6 months, the mean
(SD) 10MWT was 24.9 (23.9) and the median 16.4 s/10 m.
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Figure 1 shows a scatter plot of 10MWT at 6 months
against the baseline measure. Clearly, the variability in-
creases with increasing value of the measurement, and both
variables show a positively skewed distribution. Figure 2
shows log transformed data, where far more uniform vari-
ability is seen.
The untransformed data showed strong correlation
(r = 0.875, Fig. 1); however, this improved by using a
log scale instead, where a linear correlation between base-
line and 6-month 10MWT was observed (r = 0.938, Fig. 2).
The baseline mean (SD) and median loge 10MWT were
2.88 (0.720) and 2.77 and at 6 months 2.90 (0.743) and
2.79. It was estimated that the SD of loge10MWTafter ad-
justment for the baseline measurement was 0.258. The
mean (SD) % deterioration of 10MWT over 6 months was
an increase in time of 5.74 % (28.2 %).
Table 1 shows the detectable change in 10MWTcalcula-
tions, given a fixed sample size, for the 10MWT in pa-
tients with HAM/TSP for SD of ±0.2, 0.26 and 0.3, using
log transformed data. With 30 participants per group and
SD = 0.26, a power of 90 % to detect a decrease due to an
intervention in 10MWT of 19.85 % at 6 months can be
achieved. To power the trial at 90 %, a minimum of 33–35
patients are needed in each arm, to allow for 10–15 % esti-
mated trial drop-out rate (Fig. 3).
Discussion
A double-blind randomised controlled trial (DB RCT)
gives the highest level of evidence and is particularly im-
portant when testing novel treatments in conditions that
vary, progress slowly or are subject to placebo effect. Al-
though endemic in parts of the world, globally HAM/TSP
Fig. 1 Measured 10MWT at baseline and 6 months, with line of
equality. Different shapes represent patients from different countries.
10MWT = 10-min walking time; sec = seconds
Fig. 2 Loge10MWT at baseline and 6 months, with line of equality.
Different shapes represent patients from different countries.
10MWT = 10 min-walking time; sec = seconds
Table 1 Detectable change calculations given fixed sample size
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is a rare disease, which makes large DB RCTs difficult to
conduct [5]. This is one of the reasons why although there
are estimated 300,000–450,000 HAM/TSP patients glo-
bally, there is no internationally agreed specific treatment.
Since HTLV was discovered and associated to HAM/TSP,
there have been only two RCTs [16, 17] of which only one
was double-blind [17].
In order to provide HAM/TSP patients with a DB RCT,
we developed several strategies. An international consor-
tium was established, pooling expertise from HTLV centres
based on four continents, to prioritise and sequentially test
potential interventions for HAM/TSP. 10MWT was pro-
posed as a clinical outcome measure which would be
meaningful, reliable and easy to collect at different trial
sites. Data obtained from patients under follow-up at each
centre were collated to allow robust power calculations to
ensure optimal study design. These longitudinal data on
10MWT were used to calculate the inter- and intra-patient
variability.
Given the rarity of the condition, power calculations
should be based on robust data to ensure efficient utilisa-
tion of scarce resources, human and financial. Data are
presented on the predicted size of effect against required
sample size. The selected sample size of 33 patients per
arm for the planned comparison of active treatment with
placebo has 90 % power to detect a 20 % difference in time
taken to walk 10 m, adjusted for baseline.
10MWT had a positively skewed distribution, and the
logarithmic transformation was effective in producing an
approximately normal distribution. As a result, differences
are presented as logarithms and back transformation pro-
duces ratios. This is why detectable differences are pre-
sented as percentages rather than differences in seconds.
This study’s strengths are that data were collected longi-
tudinally, including patients from all four continents, thus
sampling the target HAM/TSP patient group. In addition,
the sample size is fairly large for a disease this rare.
10MWT may vary with gender, age, walking aid and dur-
ation of disease. However, these variables are expected to
affect the baseline and the outcome variable 10MWT in
the same way. Hence, adjustment for baseline 10MWT
removes the need to adjust for other variables.
Although there is bound to be an operator-dependent
variability of 10MWT, if the same operator carries out the
standardised baseline and outcome measurements in the
same patient, this will automatically be adjusted for by the
design.
Conclusions
In conclusion, this is the first study to report fixed sample
sizes calculated for three different SDs of loge10MWT for
clinical trials for patients with HAM/TSP powered at 80
or 90 %.
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